Glycoantigen 19-9 may refer to glycoantigen 19-9, which is a commonly used tumor marker CA19-9. This index may be more elevated in pancreatic malignancies, and other gastrointestinal malignancies may also be elevated. Generally, if this marker is elevated above 400kU/L, combined with the imaging examination and the finding of occupying lesions in the pancreas, a clinical diagnosis of pancreatic cancer can be made. Of course, it is more difficult to do puncture pathology for pancreatic cancer, and many of them cannot be obtained, but the diagnosis can also be made based on imaging tests and the index of glycoantigen 19-9 alone. The diagnosis and treatment of pancreatic cancer are very difficult. Early stage of pancreatic cancer can be cured by surgery, mainly pancreatic and duodenal resection. In the middle and late stages, many treatments are not effective, but palliative chemotherapy or local radiotherapy can prolong the survival period.